Characteristic | Values for: | ||
---|---|---|---|

Group A (A1 + A2)^{a} | Group B (B1 + B2)^{b} | Group C^{c} | |

Mean (SD) age (yr)^{d} | 23.9 (6.6) | 25.0 (6.6) | 24.9 (5.9) |

No. (%) of participants in the following age group: | |||

18–30 yr | 43 (86) | 40 (80) | 42 (84) |

31–45 yr | 7 (14) | 10 (20) | 8 (16) |

No. (%) of participants of the following gender^{d}: | |||

Male | 23 (46) | 18 (36) | 26 (52) |

Female | 27 (54) | 32 (64) | 24 (48) |

↵a The participants in group A received CVD 103-HgR at 10

^{8}CFU. The 50 participants in this group were randomly allocated to one of two subgroups, with one subgroup of 25 (group A1) receiving the CVD 103-HgR vaccine on day 0 and placebo on day 14 and the other subgroup of 25 (group A2) receiving placebo on day 0 and CVD 103-HgR on day 14.↵b The participants in group B received CVD 103-HgR at 10

^{9}CFU. The 50 participants in this group were randomly allocated to one of two subgroups, with one subgroup of 25 (group B1) receiving the CVD 103-HgR vaccine on day 0 and placebo on day 14 and the other subgroup of 25 (group B2) receiving placebo on day 0 and CVD 103-HgR on day 14.↵c The participants in group B received Shanchol. The 50 participants randomly allocated to this group received one dose of Shanchol on day 0 and the second dose of Shanchol on day 14.

↵d The differences among the vaccine groups were not statistically significant by age (

*P*= 0.66 by ANOVA) or gender (*P*= 0.27 by chi-square test).